Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Catalyst Pharm Inc (NASDAQ: CPRX)

$1.81 USD -$0.04 (-2.16%)
Last Price $1.81
Net Change $-0.04 (-2.16%)
Bid $0
Ask Price $0
Open Price $1.87
Previous Close Price $1.85
High Price $1.87
Low Price $1.78
Number of Trades 829
Volume 450,728
Fifty Two Week High $2.17 (2017-03-28)
Fifty Two Week Low $0.55 (2016-05-18)
Average Daily Volume 1,027,963
Share Outstanding 82,970 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $-17.39
Recent Earnings $
Annual EPS $-0.16
Last Quarter EPS $
Market Capitalization $0.15B
Insider Shareholders % 0.0879%
Annual Revenue $0B
No. Shares Outstanding 82,970
Inst. Shareholder % 28.8%
Annual Net Income $0B
TTM Net Profit Margin $100.13
1-Year Return 193.65%
3-Year Return -7.5%
5-Year Return 86.87%
5-Year Revenue Growth 0%
5-Year Earnings Growth -17.86%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -17.389999%
Dividends per Share $
Stock Split Ratio
Beta 2.16
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.